Earnings Summary

Amylyx Pharmaceuticals, Inc.’s revenue jumped 29666.09% since last year same period to $102.69Mn in the Q3 2023. On a quarterly growth basis, Amylyx Pharmaceuticals, Inc. has generated 4.56% jump in its revenue since last 3-months.

Amylyx Pharmaceuticals, Inc.’s net profit jumped 138.87% since last year same period to $20.89Mn in the Q3 2023. On a quarterly growth basis, Amylyx Pharmaceuticals, Inc. has generated -5.35% fall in its net profits since last 3-months.

Amylyx Pharmaceuticals, Inc.’s net profit margin jumped 100.13% since last year same period to 20.35% in the Q3 2023. On a quarterly growth basis, Amylyx Pharmaceuticals, Inc. has generated -9.48% fall in its net profit margins since last 3-months.

Amylyx Pharmaceuticals, Inc.’s price-to-earnings ratio after this Q3 2023 earnings stands at 1264.

Amylyx Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current quarter stand at 0.18 - a -59.09% fall from last quarter’s estimates.

Amylyx Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current year stand at 0.18.

Amylyx Pharmaceuticals, Inc.’s earning per share (EPS) jumped 132.61% since last year same period to 0.3 in the Q3 2023. This indicates that the Amylyx Pharmaceuticals, Inc. has generated 132.61% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Amylyx Pharmaceuticals, Inc.’s return on assets (ROA) stands at -0.01.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Amylyx Pharmaceuticals, Inc.’s return on equity (ROE) stands at 0.01.